Baby’s Death in Spinal Muscular Atrophy Gene Therapy Trial Could be Linked to Treatment, Company Says
geralt / Pixabay

Baby’s Death in Spinal Muscular Atrophy Gene Therapy Trial Could be Linked to Treatment, Company Says

According to a story from BNN Bloomberg, Novartis AG, a drug company that is nearing the completion of the development of a potentially groundbreaking new gene therapy for spinal muscular…

Continue Reading Baby’s Death in Spinal Muscular Atrophy Gene Therapy Trial Could be Linked to Treatment, Company Says

Rare Diseases: Only 10% of India’s 1.37 Billion People Have Health Insurance

In about five years India’s population will exceed that of China which is currently ranked number one according to population. Contrast these numbers with the fact that only ten percent…

Continue Reading Rare Diseases: Only 10% of India’s 1.37 Billion People Have Health Insurance
Recent Study Indicates That SPINRAZA can Benefit Patients with Late-Onset Spinal Muscular Atrophy
Pexels / Pixabay

Recent Study Indicates That SPINRAZA can Benefit Patients with Late-Onset Spinal Muscular Atrophy

According to a story from globenewswire.com, the biotechnology company Biogen recently released data from an open label study that was testing the company's spinal muscular atrophy drug nusinersen (marketed as…

Continue Reading Recent Study Indicates That SPINRAZA can Benefit Patients with Late-Onset Spinal Muscular Atrophy

New Drug Under Review by the FDA to Treat the Most Lethal Form of Spinal Muscular Atrophy

  According to an article in Biospace, the FDA is currently reviewing data from the Phase III STRIVE clinical trial for possible approval of Zolgensma as gene therapy for spinal…

Continue Reading New Drug Under Review by the FDA to Treat the Most Lethal Form of Spinal Muscular Atrophy
More Evidence Suggesting Nusinersen Effective for Spinal Muscular Atrophy Types II and III
kkolosov / Pixabay

More Evidence Suggesting Nusinersen Effective for Spinal Muscular Atrophy Types II and III

According to a press release from the American Academy of Neurology published by EurekAlert, new research published in Neurology further suggests that established spinal muscular atrophy (SMA) drug nusinersen could…

Continue Reading More Evidence Suggesting Nusinersen Effective for Spinal Muscular Atrophy Types II and III
Latest Data Reinforces Effectiveness of a Potential Gene Therapy for Type 1 Spinal Muscular Atrophy
skeeze / Pixabay

Latest Data Reinforces Effectiveness of a Potential Gene Therapy for Type 1 Spinal Muscular Atrophy

According to a story from inpublic.globenewswire.com, the Novartis company AveXis has released interim data from an ongoing Phase 3 clinical trial of Zolgensma, a gene therapy drug that is being…

Continue Reading Latest Data Reinforces Effectiveness of a Potential Gene Therapy for Type 1 Spinal Muscular Atrophy
Gene Therapy Could Change Rare Disease Treatment Forever, But Will Anyone be Able to Afford It?
8385 / Pixabay

Gene Therapy Could Change Rare Disease Treatment Forever, But Will Anyone be Able to Afford It?

According to a story from BNN Bloomberg, gene therapies are without a doubt an upcoming advancement in care and treatment for many diseases that have a genetic origin. This includes…

Continue Reading Gene Therapy Could Change Rare Disease Treatment Forever, But Will Anyone be Able to Afford It?
Study Indicates Safety of New Potential Treatment for Swallowing Dysfunction in Kennedy Disease
source: pixabay.com

Study Indicates Safety of New Potential Treatment for Swallowing Dysfunction in Kennedy Disease

Kennedy disease or, Spinal and Bulbar Muscular Atrophy (SBMA) is a form of Spinal Muscular Atrophy (SMA). SBMA causes muscle weakness throughout the limbs which results in impaired mobility (typical…

Continue Reading Study Indicates Safety of New Potential Treatment for Swallowing Dysfunction in Kennedy Disease
Bioscience Companies in Ohio Take Aim at Rare Diseases
source: pixabay.com

Bioscience Companies in Ohio Take Aim at Rare Diseases

According to a story from BioPortfolio, Rare Disease Day, which took place on February 28th, 2019, serves as a time of reflection on the progress that has been made in…

Continue Reading Bioscience Companies in Ohio Take Aim at Rare Diseases

New Treatment for Familial Chylomicronemia Syndrome is Close to Approval in the EU

Familial Chylomicronemia Syndrome Familial chylomicronemia syndrome (FCS) is a condition that is considered ultra-rare. It's caused when the enzyme called lipoprotein lipase (LPL) is impaired. It is can result in…

Continue Reading New Treatment for Familial Chylomicronemia Syndrome is Close to Approval in the EU
Passage Bio Receives New Funding to Advance 5 Gene Therapy Projects
Source: Pixabay

Passage Bio Receives New Funding to Advance 5 Gene Therapy Projects

Passsage Bio Passage Bio has just announced that they've received 115.5 million dollars to help advance their development of gene therapies. They will begin by using the funds to further…

Continue Reading Passage Bio Receives New Funding to Advance 5 Gene Therapy Projects
Choroideremia Can Lead to Blindness – But Gene Therapy Might Be Able to Halt It
Source: Pixabay

Choroideremia Can Lead to Blindness – But Gene Therapy Might Be Able to Halt It

An article recently published by the Guardian shared the stories of three families affected by recent breakthroughs in gene therapy treatments. What is Gene Therapy? Gene therapy is an increasingly…

Continue Reading Choroideremia Can Lead to Blindness – But Gene Therapy Might Be Able to Halt It